Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283472 | 0.84 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4EGAALMNA | |
| SCHEMBL9271743 | 0.83 | ALDH1A1 (0.67) | ALDH1A1HPGDKDM4EGAALMNA | |
| SCHEMBL10401087 | 0.83 | ALDH1A1 (0.70) | ALDH1A1HPGDKDM4EGAALMNA | |
| SCHEMBL2094345 | 0.81 | ALDH1A1 (0.64) | ALDH1A1HPGDKDM4EGAALMNA | |
| SCHEMBL10959203 | 0.81 | HPGD (0.78) | ALDH1A1HPGDKDM4EGAALMNA | |
| SCHEMBL9523920 | 0.81 | ALDH1A1 (0.68) | ALDH1A1HPGDKDM4EGAALMNA | |
| SCHEMBL10959557 | 0.80 | ALDH1A1 (0.71) | ALDH1A1HPGDKDM4EGAALMNA | |
| SCHEMBL283066 | 0.80 | ALDH1A1 (0.71) | ALDH1A1HPGDKDM4EGAALMNA | |
| SCHEMBL9813594 | 0.79 | ALDH1A1 (0.74) | ALDH1A1HPGDKDM4EGAALMNA | |
| Acrylic Acid SCHEMBL17822133 | 0.79 | ALDH1A1 (0.82) | ALDH1A1HPGDKDM4EGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117264004-A | Compound and nucleic acid synthesis method | 深圳华大生命科学研究院 | 2023-12-22 | — | — | CN | claimed |
| CN-110678447-B | Modified nucleic acid monomer compounds and oligonucleotide analogues | 卫材R&D管理有限公司 | 2023-12-12 | — | — | CN | claimed |
| EP-3643706-B1 | MODIFIED NUCLEIC ACID MONOMERS AND OLIGONUCLEIC ACID ANALOGUES, WITH HIGH BIOLOGICAL STABILITY AND TARGET GENE SILENCING ACTIVITY, FOR USE IN THERAPY AND DIAGNOSIS OF CANCER AND VIRAL DISEASES | EISAI R&D MAN CO LTD (JP) | 2023-11-15 | — | — | EP | claimed |
| US-9714560-B2 | Protected scale inhibitors and methods relating thereto | HALLIBURTON ENERGY SERVICES, INC. (US) | 2017-07-25 | — | — | US | claimed |
| US-20020147331-A1 | Methods for synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2002-10-10 | — | — | US | claimed |
| WO-2002062811-A2 | IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2002-08-15 | — | — | WO | claimed |
| CN-117264004-A | Compound and nucleic acid synthesis method | 深圳华大生命科学研究院 | 2023-12-22 | — | — | CN | disclosed |
| CN-110678447-B | Modified nucleic acid monomer compounds and oligonucleotide analogues | 卫材R&D管理有限公司 | 2023-12-12 | — | — | CN | disclosed |
| EP-3643706-B1 | MODIFIED NUCLEIC ACID MONOMERS AND OLIGONUCLEIC ACID ANALOGUES, WITH HIGH BIOLOGICAL STABILITY AND TARGET GENE SILENCING ACTIVITY, FOR USE IN THERAPY AND DIAGNOSIS OF CANCER AND VIRAL DISEASES | EISAI R&D MAN CO LTD (JP) | 2023-11-15 | — | — | EP | disclosed |
| US-11208429-B2 | Modified nucleic acid monomer compound and oligonucleic acid analog | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-12-28 | — | — | US | disclosed |
| US-10874740-B2 | 5-ALA derivatives and use thereof | UNIVERSITE DE GENEVE (CH) | 2020-12-29 | — | — | US | disclosed |
| EP-3643706-A9 | MODIFIED NUCLEIC ACID MONOMER COMPOUND AND OLIGONUCLEIC ACID ANALOG | Eisai R&D Management Co., Ltd. (JP) | 2020-09-23 | — | — | EP | disclosed |
| US-20200216488-A1 | MODIFIED NUCLEIC ACID MONOMER COMPOUND AND OLIGONUCLEIC ACID ANALOG | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-07-09 | — | — | US | disclosed |
| EP-2915815-A1 | NEW MODIFIED NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014200757-A1 | PROTECTED SCALE INHIBITORS AND METHODS RELATING THERETO | HALLIBURTON ENERGY SERVICES, INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20140367101-A1 | Protected Scale Inhibitors and Methods Relating Thereto | HALLIBURTON ENERGY SERVICES, INC. | 2014-12-18 | — | — | US | disclosed |
| US-8138330-B2 | Solid phase synthesis via deblocking immobilized nucleoside, then coupling acyl protected nucleoside phosphoramidite | SIGMA-ALDRICH CO. LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20080064867-A1 | PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | SIGMA ALDRICH COMPANY (US) | 2008-03-13 | — | — | US | disclosed |
| US-20020147331-A1 | Methods for synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002062811-A2 | IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216488-A1 | MODIFIED NUCLEIC ACID MONOMER COMPOUND AND OLIGONUCLEIC ACID ANALOG | POLRMT, DERA, PCNA | ALDH1A1 2175/4885HPGD 1535/4885KDM4E 3391/4885 |
| US-20080064867-A1 | PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | RNGTT, DUT, ADAR | ALDH1A1 2127/4885HPGD 4031/4885KDM4E 1717/4885 |
| US-11208429-B2 | Modified nucleic acid monomer compound and oligonucleic acid analog | POLRMT, DERA, PCNA | ALDH1A1 2175/4885HPGD 1535/4885KDM4E 3391/4885 |
| US-10874740-B2 | 5-ALA derivatives and use thereof | ALAD, ANXA5, AAAS | ALDH1A1 76/4885HPGD 249/4885KDM4E 1819/4885 |
| US-20020147331-A1 | Methods for synthesis of oligonucleotides | RNGTT, TYMP, PNP | ALDH1A1 4843/4885HPGD 3858/4885KDM4E 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.